Zacks Research Estimates Novavax’s Q4 Earnings (NASDAQ:NVAX)

Novavax, Inc. (NASDAQ:NVAX) – Research analysts at Zacks Research lowered their Q4 2026 earnings estimates for Novavax in a research report issued to clients and investors on Wednesday, February 26th. Zacks Research analyst S. Ganoria now anticipates that the biopharmaceutical company will post earnings per share of $0.40 for the quarter, down from their prior forecast of $0.45. The consensus estimate for Novavax’s current full-year earnings is ($1.46) per share.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.51) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.24. The firm had revenue of $88.31 million during the quarter, compared to the consensus estimate of $85.48 million. During the same quarter in the previous year, the company posted ($1.44) earnings per share.

Several other research firms also recently issued reports on NVAX. BTIG Research initiated coverage on Novavax in a research note on Friday. They issued a “buy” rating and a $19.00 price objective for the company. HC Wainwright restated a “buy” rating and issued a $19.00 price target on shares of Novavax in a research report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $18.00.

Novavax Trading Up 18.0 %

Novavax stock opened at $8.33 on Friday. The stock has a 50-day moving average price of $8.52 and a two-hundred day moving average price of $10.00. Novavax has a 12 month low of $3.81 and a 12 month high of $23.86. The company has a market capitalization of $1.33 billion, a PE ratio of -3.69, a P/E/G ratio of 2.85 and a beta of 2.14.

Institutional Investors Weigh In On Novavax

Several institutional investors and hedge funds have recently made changes to their positions in NVAX. Charles Schwab Investment Management Inc. boosted its holdings in shares of Novavax by 16.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,325,508 shares of the biopharmaceutical company’s stock worth $16,741,000 after buying an additional 187,548 shares in the last quarter. Bank of Montreal Can lifted its position in shares of Novavax by 26.7% during the 3rd quarter. Bank of Montreal Can now owns 2,454,325 shares of the biopharmaceutical company’s stock valued at $32,643,000 after acquiring an additional 517,727 shares during the period. State Street Corp lifted its position in shares of Novavax by 26.7% during the 3rd quarter. State Street Corp now owns 7,687,951 shares of the biopharmaceutical company’s stock valued at $97,099,000 after acquiring an additional 1,621,772 shares during the period. Franklin Resources Inc. boosted its stake in Novavax by 300.4% during the third quarter. Franklin Resources Inc. now owns 97,162 shares of the biopharmaceutical company’s stock worth $1,226,000 after acquiring an additional 72,894 shares in the last quarter. Finally, Shah Capital Management grew its holdings in Novavax by 13.6% in the fourth quarter. Shah Capital Management now owns 11,148,846 shares of the biopharmaceutical company’s stock worth $89,637,000 after purchasing an additional 1,333,305 shares during the period. Institutional investors own 53.04% of the company’s stock.

Insider Buying and Selling at Novavax

In related news, Director Rachel K. King sold 4,150 shares of the business’s stock in a transaction on Friday, December 13th. The shares were sold at an average price of $9.02, for a total value of $37,433.00. Following the transaction, the director now owns 14,770 shares in the company, valued at $133,225.40. The trade was a 21.93 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director James F. Young sold 5,400 shares of the stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $8.00, for a total value of $43,200.00. Following the sale, the director now owns 51,760 shares of the company’s stock, valued at approximately $414,080. The trade was a 9.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 14,150 shares of company stock valued at $119,641. 1.00% of the stock is currently owned by company insiders.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.